source
- EnGene reports improved bladder cancer data after May setbackEnGene, a biotech developing a bladder cancer therapy, released new data that appear more encouraging than the results disclosed in May. The May data had shown limited durability, causing a sharp…
- BioNTech spends $205 million to buy Scholar Rock’s FDA priority-review voucher as J&J scales back in NorwayBioNTech announced it has purchased an FDA priority review voucher from Scholar Rock for $205 million. The voucher, which can be used to accelerate the regulatory review of a future drug, was origi…